Product DescriptiongoogleThe Biosensis proBDNF RapidTM enzyme-linked immunosorbent assay (ELISA) Kit is a sandwich ELISA that allows the specific, fast and reliable quantification of proBDNF in less than 4 hours in cell culture supernatants, cell lysates, serum, citrate-plasma and tissue extracts only if used as directed. Please refer to the kit protocol for specific use instructions for each substrate application, in particular human blood samples.
This ELISA kit consists of a pre-coated polyclonal anti-proBDNF capture antibody, a biotinylated anti-matureBDNF detection antibody and horseradish peroxidase (HRP)-conjugated streptavidin. The addition of a substrate (3,3',5,5'-tetramethylbenzidine, TMB) yields a colored reaction product which is directly proportional to the concentration of proBDNF present in samples and protein standards. A proBDNF positive control (QC sample) is provided to assure consistent assay performance.
This proBDNF ELISA kit employs a recombinant, cleavage-resistant human proBDNF standard produced by Biosensis and validated against externally available proBDNF proteins.
Due to a high degree of amino acid sequence homology, mouse and rat proBDNF can be quantified and expressed as human proBDNF equivalents. Internal Biosensis validation suggests that the use of the human standard provided in this kit will provide estimates that are identical, or close, to the actual levels of rat and mouse proBDNF present in rodent samples.
Note that accurate proBDNF quantification in human serum and citrate-plasma requires the addition of Heterophilic Antibody Blocker BL-004-500 provided in the kit, and available for purchase separately.
This ELISA kit has not been tested for other applications. It has been configured for research use only and is not to be used for diagnostic or clinical procedures.
Alternative NamesBrain-derived neurotrophic factor; BDNF; Abrineurin
Application(s)ELISA
Species ReactivityHuman, Mouse, Rat
Immunogen DescriptionRecombinant human proBDNF, mutated to be cleavage-resistant, made in 293F cells
Range15.6 - 1,000 pg/mL
SensitivityTypical limit of detection (LOD) for proBDNF is 10 pg/mL determined as 150% of the blank value.
Product DescriptionThe Biosensis proBDNF RapidTM enzyme-linked immunosorbent assay (ELISA) Kit is a sandwich ELISA that allows the specific, fast and reliable quantification of proBDNF in less than 4 hours in cell culture supernatants, cell lysates, serum, citrate-plasma and tissue extracts only if used as directed. Please refer to the kit protocol for specific use instructions for each substrate application, in particular human blood samples.
This ELISA kit consists of a pre-coated polyclonal anti-proBDNF capture antibody, a biotinylated anti-matureBDNF detection antibody and horseradish peroxidase (HRP)-conjugated streptavidin. The addition of a substrate (3,3',5,5'-tetramethylbenzidine, TMB) yields a colored reaction product which is directly proportional to the concentration of proBDNF present in samples and protein standards. A proBDNF positive control (QC sample) is provided to assure consistent assay performance.
This proBDNF ELISA kit employs a recombinant, cleavage-resistant human proBDNF standard produced by Biosensis and validated against externally available proBDNF proteins.
Due to a high degree of amino acid sequence homology, mouse and rat proBDNF can be quantified and expressed as human proBDNF equivalents. Internal Biosensis validation suggests that the use of the human standard provided in this kit will provide estimates that are identical, or close, to the actual levels of rat and mouse proBDNF present in rodent samples.
Note that accurate proBDNF quantification in human serum and citrate-plasma requires the addition of Heterophilic Antibody Blocker BL-004-500 provided in the kit, and available for purchase separately.
This ELISA kit has not been tested for other applications. It has been configured for research use only and is not to be used for diagnostic or clinical procedures.
Application DetailsELISA. For the quantification of Brain-derived neurotrophic factor, pro- (proBDNF) in Culture Supernatant, Cell Lysates, Serum, Plasma (Citrate), Tissue Homogenates. Please download the detailed product insert for complete instructions for the successful use of this ELISA. Use only as directed.
Target Cross-Reactivity (ELISA)A cross-reactivity of 2% in weight concentration (0.9% in molar concentration) has been observed for mature BDNF assayed at 25 ng/mL (893 pmol/L) in Assay Diluent A. Due to a high degree of sequence homology, this human proBDNF ELISA kit cross-reacts with the mouse and rat form of proBDNF. Other species have not yet been tested, but cross-reactivity with a wide range of mammalian forms of proBDNF is expected. The antibodies do not cross-react with nerve growth factor (NGF), neurotrophin-3 (NT-3) or NT-4/5.
Target Host SpeciesHuman
Species ReactivityHuman, Mouse, Rat
Immunogen DescriptionRecombinant human proBDNF, mutated to be cleavage-resistant, made in 293F cells
Range15.6 - 1,000 pg/mL
SensitivityTypical limit of detection (LOD) for proBDNF is 10 pg/mL determined as 150% of the blank value.
Scientific BackgroundBDNF belongs to the neurotrophin family and regulates the survival and differentiation of neurons during development. The alterations in BDNF expression induced by various kinds of brain insult including stress, ischemia, seizure activity and hypoglycemia, may contribute to some pathologies such as depression, epilepsy, Alzheimer's, and Parkinson's disease. FUNCTION: Promotes the survival of neuronal populations that are all located either in the central nervous system or directly connected to it. Major regulator of synaptic transmission and plasticity at adult synapses in many regions of the CNS. The versatility of BDNF is emphasized by its contribution to a range of adaptive neuronal responses including long-term potentiation (LTP), long-term depression (LTD), certain forms of short-term synaptic plasticity, as well as homeostatic regulation of intrinsic neuronal excitability. SUBUNIT: Monomers and homodimers. Binds to NTRK2/TRKB. SUBCELLULAR LOCATION: Secreted protein. Post Translation Modification (PTM): The propeptide is N-glycosylated and glycosulfated. PTM: Converted into mature BDNF by plasmin (PLG) (By similarity). DISEASE: Defects in BDNF are a cause of congenital central hypoventilation syndrome (CCHS); also known as congenital failure of autonomic control or Ondine curse. CCHS is a rare disorder characterized by abnormal control of respiration in the absence of neuromuscular or lung disease, or an identifiable brain stem lesion. A deficiency in autonomic control of respiration results in inadequate or negligible ventilatory and arousal responses to hypercapnia and hypoxemia. CCHS is frequently complicated with neurocristopathies such as Hirschsprung disease that occurs in about 16% of CCHS cases. SIMILARITY: Belongs to the NGF-beta family.
Shipping StatementFor order quantities larger than 1 plate, this product is supplied in package units of 2 plates.
This standard curve generated in our laboratories is for demonstration purposes only, but can be used as a guide to expected performance. A standard curve should be generated for each assay.
Specific quantification of full-length proBDNF in the proBDNF RapidTM ELISA kit (BEK-2217).
Specific ReferencesYu T et al. (2022) "Multisession Anodal Transcranial Direct Current Stimulation Enhances Adult Hippocampal Neurogenesis and Context Discrimination in Mice" J. Neurosci. 10.1523Application: Mouse, Brain tissue homogenate.
Huang R et al. (2022) "Endothelial LRP1-ICD Accelerates Cognition-Associated Alpha-Synuclein Pathology and Neurodegeneration through PARP1 Activation in a Mouse Model of Parkinson's Disease" Mol Neurobiol. [Epub ahead of print].Application: Mouse Cell lysates.
Aldhshan MS & Mizuno TM. (2022) "Effect of environmental enrichment on aggression and the expression of brain-derived neurotrophic factor transcript variants in group-housed male mice." Behav Brain Res. [Epub ahead of print].Application: Mouse Brain tissue homogenate.
Dorandish S et al. (2021) "Differences in the Relative Abundance of ProBDNF and Mature BDNF in A549 and H1299 Human Lung Cancer Cell Media." Int J Mol Sci. 22(13):7059.Application: Human culture supernatant.
Payne AJ (2020) "The Effects of Alcohol on BDNF and CD5 Dependent Pathways." PhD Thesis.Application: Mouse RIPA tissue homogenates.
Companys-Alemany J et al. (2020) "A Novel NMDA Receptor Antagonist Protects against Cognitive Decline Presented by Senescent Mice." Pharmaceutics. 12(3), 284.Application: Mouse hippocampal homogenates.
Duart-Castells L et al. (2019) "7,8-dihydroxyflavone blocks the development of behavioral sensitization to MDPV, but not to cocaine: differential role of the BDNF-TrkB pathway." Biochem Pharmacol. [Epub ahead of print].Application: Mouse RIPA tissue homogenates.
Osborne A, Wang AX, Tassoni A, Widdowson PS, Martin KR (2018) "Design of a Novel Gene Therapy Construct to Achieve Sustained Brain-Derived Neurotrophic Factor Signalling in Neurons." Hum Gene Ther. [Epub ahead of print].Application: Human cell line supernatant.
Rahman MS, Millischer V, Zeebari Z, Forsell Y, Lavebratt C (2017) "BDNF Val66Met and childhood adversity on response to physical exercise and internet-based cognitive behavioural therapy in depressed Swedish adults." J Psychiatr Res. 93:50-58.Application: Human serum.
Riffault B, Kourdougli N, Dumon C, Ferrand N, Buhler E, Schaller F, Chambon C, Rivera C, Gaiarsa JL, Porcher C (2016) "Pro-Brain-Derived Neurotrophic Factor (proBDNF)-Mediated p75NTR Activation Promotes Depolarizing Actions of GABA and Increases Susceptibility to Epileptic Seizures". Cereb. Cortex [Epub ahead of print].Application: Rat cortex and hippocampus RIPA extracts.
Hashimoto T, Shiina A, Hasegawa T, Kimura H, Oda Y, Niitsu T, Ishikawa M, Tachibana M, Muneoka K, Matsuki S, Nakazato M, Iyo M (2016) "Effect of mirtazapine versus selective serotonin reuptake inhibitors on benzodiazepine use in patients with major depressive disorder: a pragmatic, multicenter, open-label, randomized, active-controlled, 24-week trial." Ann Gen Psychiatry. 15(27).Application: Human serum.
Niimi M, Hashimoto K, Kakuda W, Miyano S, Momosaki R, Ishima T, Abo M. (2016) "Role of Brain-Derived Neurotrophic Factor in Beneficial Effects of Repetitive Transcranial Magnetic Stimulation for Upper Limb Hemiparesis after Stroke." PLoS One. 11(3):e0152241.Application: Human serum.
Stary CM, Sun X, Giffard RG (2015) "Astrocytes Protect against Isoflurane Neurotoxicity by Buffering pro-brain-derived Neurotrophic Factor." Anesthesiology. 123(4):810-9.Application: Rat neuron and astrocyte cell culture supernatant.
Riffault B, Medina I, Dumon C, Thalman C, Ferrand N, Friedel P, Gaiarsa JL, Porcher C. (2014) "Pro-Brain-Derived Neurotrophic Factor Inhibits GABAergic Neurotransmission by Activating Endocytosis and Repression of GABAA Receptors." J. Neurosci. 34(40):13516-34.Application: Rat hippocampal culture supernatant.